Satellos Bioscience (MSCL) 2026 Bloom Burton & Co. Healthcare Investor Conference summary

Strategic direction and clinical milestones

• Positioned to deliver meaningful clinical data and pursue drug approval for Duchenne muscular dystrophy (DMD) by 2026, with accelerated approval targeted for 2027.

• Focused on a novel, oral, non-genetic therapy aimed at restoring muscle regeneration by targeting muscle stem cells, suitable for all DMD patients regardless of genetic background or age.

• Two concurrent phase II trials underway: BASECAMP in children (ages 7–9) and TRAILHEAD in adults (16+), with data expected in 2026.

• BASECAMP is a placebo-controlled, double-blind study across 25 sites in eight countries, enrolling patients on standard care and those previously treated with gene therapy or exon skipping.

• Plans to expand clinical development into FSHD, another muscle disease, and to open TRAILHEAD in the U.S. in Q2.

Clinical data and scientific insights

• Preclinical canine studies and phase I/II human trials show significant improvements in muscle strength and durability of effect, including a doubling of grip strength sustained over a year.

• Drug demonstrates rapid onset of action, clean safety profile, and is well-tolerated with no significant side effects observed to date.

• Proteomic analysis reveals marked declines in established DMD biomarkers, indicating direct action on muscle tissue.

• Greater efficacy observed in patients with more residual muscle, supporting the rationale for pediatric trials.

• BASECAMP includes comprehensive endpoints: muscle biopsies, MRI, functional assessments, and biomarker analysis over a 12-week dosing period.

Market and payer considerations

• DMD affects 12,000 individuals in the U.S. and Canada, with current therapies offering limited benefit and significant side effects.

• Existing genetic therapies are costly (CAD 1–3 million annually) and limited to specific patient subgroups.

• Strategic trial design includes patients on standard care and those with prior gene or exon skipping therapies to maximize payer acceptance.

• No parallel physical therapy is included in the trials.

• No current concerns about payers restricting use to patients who have failed other therapies; all DMD patients eventually progress.